Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoImmuneTech has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug, NT-I7 (efineptakin alfa) (rhIL-7-hyFc), to treat Acute Radiation Syndrome (ARS), an acute illness.
The company is planning studies for testing the therapy in additional solid tumours. Credit: Logan Moreno Gutierrez on Unsplash.
Subscribe to our email newsletter
The clinical-stage long-acting human IL-7, NT-I7 is being developed in oncologic and immunologic indications.
In these indications, T cell amplification and increased functionality are expected to provide clinical benefit.
The therapy exhibits favourable PK/PD and safety profiles and is being studied in multiple clinical trials in solid tumours and as a vaccine adjuvant.
The company is planning studies for testing the therapy in additional solid tumours, haematologic malignancies, and other immunology-focused indications.
NeoImmuneTech president and CEO Dr Se Hwan Yang said: “Obtaining the orphan drug designation from the FDA is an important acknowledgment of the immense potential that NT-I7 holds in providing a beacon of hope for the treatment of ARS.”
ARS is caused by irradiation of the entire body by a high dose of penetrating radiation in a short period of time and leads to severe damage to the bone marrow and the immune system.
In the clinical setting, NT-I7 has demonstrated positive results by boosting T cell counts consistently, while maintaining a good level of tolerance and safety.
The ODD is aimed at advancing treatments for rare diseases, including ARS, which has limited treatment options at present.
